Antonella Villa
University of Milan
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Antonella Villa.
European Journal of Cancer | 2000
Z. Benderra; A. Trussardi; H. Morjani; Antonella Villa; Silvia Maria Doglia; M. Manfait
Multidrug resistance (MDR) is frequently associated with the overexpression of P-glycoprotein (Pgp) and/or multidrug resistance associated protein (MRP1), both members of the ABC superfamily of transporters. Pgp and MRP1 function as ATP-dependent efflux pumps that extrude cytotoxic drugs from tumour cells. Glutathione (GSH) has been considered to play an important role in the MRP1-mediated MDR. In our study, we examined the effects of buthionine sulphoximine (BSO), an inhibitor of GSH biosynthesis, on the nuclear accumulation of daunorubicin (DNR), in etoposide (VP16) and doxorubicin (ADR) resistant MCF7 cell lines, overexpressing respectively MRP1 (MCF7/VP) and Pgp (MCF7/ADR). The study of DNR transport was carried out using scanning confocal microspectrofluorometry. This technique allows the determination of the nuclear accumulation of anthracyclines in single living tumour cells. Treatment of MCF7/VP cells with BSO increased the sensitivity of these cells to DNR whilst the cytotoxicity of the drug in MCF7/ADR cells remained unchanged. In MCF7 resistant cells treated with BSO, their GSH level decreased as observed by confocal microscopy. DNR nuclear accumulation in MCF7/VP cells was increased by BSO whereas in MCF7/ADR cells BSO was unable to significantly increase the DNR nuclear accumulation. These data suggest a requirement for GSH in MRP1-mediated resistance whilst the nuclear efflux of GSH conjugates is probably not the primary mechanism of Pgp-mediated MDR. Finally, BSO might be a useful agent in clinical assays for facilitating detection of MRP1 expression.
Tumori | 1999
Giovanna Scarfone; Antonella Villa; Fabio Parazzini; Cesarina Sciatta; Giampiero Polverino; Giorgio Bolis
Aims and Background To evaluate the toxicity of high-dose ifosfamide in ovarian cancer patients refractory or resistant to platinum and/or paclitaxel-containing chemotherapy. Methods This was an open, non-randomized phase I-II trial of high-dose ifosfamide. Eligibility criteria were: patients aged 18-75 years affected by ovarian cancer with refractory or resistant disease or early relapse after first-line treatment including platinum or paclitaxel. Three patients were given escalating ifosfamide doses; if no severe adverse events occurred, the ifosfamide dose was increased. The starting dose of ifosfamide was 10 g/m2 iv and the dose increase was 1 g/m2 every four weeks for a total of five courses; 12 g/m2 was the maximum ifosfamide dose to be administered. The trial then progressed to a phase II trial, in which ifosfamide was given at the maximum tolerated dose reached during the escalating dose phase. Results A total of 36 patients entered the trial. Nine patients were involved in phase I of the study; 3 received 10 g/m2 ifosfamide, 3 11 g/m2 and 3 12 g/m2. Of the 32 evaluable patients 6 (18.8%) achieved a complete response and three (9.4%) a partial response, giving an overall response rate of 28.1% (95% CI, 15-61% based on Poissons approximation). The median number of ifosfamide courses was five. G1, G2 and G3 neurotoxicity was reported in 3 (8%), 2 (5%) and 2 (5%) patients, respectively. Conclusion This phase I-II trial indicates that high-dose ifosfamide has some activity but also a relevant degree of toxicity in resistant or refractory platinum and paclitaxel-pretreated ovarian cancer.
European Journal of Cancer | 1997
Giorgio Bolis; Giovanna Scarfone; Flavia Zanaboni; Antonella Villa; M. Presti; Mauro Melpignano; C. Ferraris; Saverio Tateo; Paolo Guarnerio; A. Gentile; Fabio Parazzini
We conducted a phase I-II study with escalating paclitaxel doses plus carboplatin at a fixed dose for previously untreated patients with advanced ovarian cancer in order to define the maximum tolerated dose. Eligible for the study were women with a histologically confirmed diagnosis of ovarian cancer stage III-IV according to the FIGO classification. In the first phase of the study, 6 patients were allocated escalating paclitaxel doses with fixed-dose carboplatin in order to establish the maximum tolerated dose. The starting dose of paclitaxel was 150 mg/m2 given after carboplatin (300 mg/m2) every 4 weeks for a total of six courses. The paclitaxel dose step was 25 mg/m2 up to 250 mg/m2. The study then progressed to a phase II trial using the maximum tolerated paclitaxel dosage reached during the escalating dose phase. A total of 27 patients entered phase I and 23 phase II. Neurotoxicity was observed in 47 patients (94%; 29 grade 1, 17 grade 2, 1 grade 3, according to the WHO classification). The intensity of neurotoxicity tended to be dose related: out of the 15 patients who received < or = 200 mg paclitaxel, a total of 14 grade 1, but no grade 2 or 3 neurotoxicities, were observed. The frequency of grade 1, 2 and 3 neurotoxicity was 15, 17 and 1, respectively, in the 35 women who received > or = 225 paclitaxel +300 mg carboplatin. There was no clear relationship between median WBC and platelet nadir and dose level. Among other toxicities, alopecia was observed in all 50 cases, hypersensitivity in two (4%) and myalgia in 41 (82%; 34 grade 1 and 7 grade 2). These frequencies tended to increase with the dose, but the relationship was not statistically significant. The overall response rate was 78% (39/50) with a complete response rate of 62% (31/50). In conclusion, this study suggests that carboplatin and paclitaxel can be administered safely to patients with advanced ovarian carcinoma. The maximum dose reached was 250 mg/m2 paclitaxel and 300 mg/m2 for carboplatin, but from a clinical point of view the maximum paclitaxel dose we would consider safe is 225 mg/m2.
Archive | 2015
Fabio Parazzini; Antonella Villa; Giampiero Polverino; Stefania Noli; Giovanna Scarfone
Breast cancer in young women is not a rare condition. Considering the US population, about 7 % of all cases are diagnosed before the age of 40, 2.4 % are diagnosed before age 35, and 1 % diagnosed before age 30. Breast cancer in young women has specific characteristics. In particular it has an aggressive course of clinical presentation, a higher rate of germline mutation in BRCA 1&2, distinct estrogen and progesterone receptor expression, and over-expression of human epidermal growth factor receptor 2. Further, they are partially different also in the epidemiological profile. In this chapter, we reviewed the epidemiology of breast cancer among women aged 40 years or less.
Gynecologic Oncology | 1999
Giorgio Bolis; Fabio Parazzini; Giovanna Scarfone; Antonella Villa; Mariangela Amoroso; Emanuela Rabaiotti; Anna Polatti; Simona Reina; Elena Pirletti
International Journal of Cancer | 1994
Fabio Parazzini; Carlo La Vecchia; Eva Negri; Antonella Villa
American Journal of Obstetrics and Gynecology | 2006
Laura Carlini; Antonella Villa; Luisa Busci; Gaetano Trezzi; Roberto Agazzi; Luigi Frigerio
Gynecologic Oncology | 2001
Giorgio Bolis; Giovanna Scarfone; Antonella Villa; Fabio Parazzini
European Journal of Cancer | 1995
Giorgio Bolis; Antonella Villa; C. Ferraris; L. Luchini; Fabio Parazzini
Tumori | 1998
Giorgio Bolis; Zappalà A; Antonella Villa; Polatti A; Simona Reina; Elena Pirletti
Collaboration
Dive into the Antonella Villa's collaboration.
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
View shared research outputs